

World Journal of *Clinical Cases*

World J Clin Cases 2024 January 16; 12(2): 236-465



EDITORIAL

- 236 Use of artificial intelligence in the field of pain medicine
Chang MC

ORIGINAL ARTICLE**Retrospective Study**

- 240 Ultrasound blood flow characteristics changes in fetal umbilical artery thrombosis: A retrospective analysis
Hong SJ, Hong LW, He XQ, Zhong XH
- 249 Electroencephalogram findings in 10 patients with post-stroke epilepsy: A retrospective study
Wen LM, Li R, Wang YL, Kong QX, Xia M
- 256 Exploration of cardiac rehabilitation nursing for elderly patients with myocardial infarction based on individualized cardiac rehabilitation
Liu HN, Gao B
- 267 Survival benefit of concurrent chemoradiotherapy for advanced ampulla of Vater cancer
Kwon CH, Seo HI, Kim DU, Han SY, Kim S, Lee NK, Hong SB, Ahn JH, Park YM, Noh BG
- 276 Utility of plasma D-dimer for diagnosis of venous thromboembolism after hepatectomy
Miyake T, Yanagimoto H, Tsugawa D, Akita M, Asakura R, Arai K, Yoshida T, So S, Ishida J, Urade T, Nanno Y, Fukushima K, Gon H, Komatsu S, Asari S, Toyama H, Kido M, Ajiki T, Fukumoto T
- 285 Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma
Sun SS, Guo XD, Li WD, Chen JL

Observational Study

- 293 Timing theory integrated nursing combined behavior change integrated theory of nursing on primiparous influence
He YX, Lv Y, Lan TT, Deng F, Zhang YY
- 302 Inverse relationship between platelet Akt activity and hippocampal atrophy: A pilot case-control study in patients with diabetes mellitus
Tokuda H, Hori T, Mizutani D, Hioki T, Kojima K, Onuma T, Enomoto Y, Doi T, Matsushima-Nishiwaki R, Ogura S, Iida H, Iwama T, Sakurai T, Kozawa O

Randomized Controlled Trial

- 314 Impact of continuous care on cardiac function in patients with lung cancer complicated by coronary heart disease
Gao T, Luo JL, Guo P, Hu XW, Wei XY, Hu Y

- 322 Use of cognitive-behavioral career coaching to reduce work anxiety and depression in public employees
Otu MS, Sefotho MM

META-ANALYSIS

- 335 Efficacy and safety of Yangxue Qingnao Granules in treatment of migraine: A systematic review and meta-analysis
Zhou B, Wang GS, Yao YN, Hao T, Li HQ, Cao KG

CASE REPORT

- 346 Use of MLC901 in cerebral venous sinus thrombosis: Three case reports
Arsovska AA, Venketasubramanian N
- 354 Primary biliary cholangitis presenting with granulomatous lung disease misdiagnosed as lung cancer: A case report
Feng SL, Li JY, Dong CL
- 361 Asymptomatic low-grade appendiceal mucinous neoplasm: A case report
Yao MQ, Jiang YP, Wang YY, Mou YP, Fan JX
- 367 Surgically treating a rare and asymptomatic intraductal papillary neoplasm of the bile duct: A case report
Zhu SZ, Gao ZF, Liu XR, Wang XG, Chen F
- 374 Absence of enhancement in a lesion does not preclude primary central nervous system T-cell lymphoma: A case report
Kim CS, Choi CH, Yi KS, Kim Y, Lee J, Woo CG, Jeon YH
- 383 Mental retardation, seizures and language delay caused by new SETD1B mutations: Three case reports
Ding L, Wei LW, Li TS, Chen J
- 392 Three cancers in the renal pelvis, bladder, and colon: A case report
Chen J, Huang HY, Zhou HC, Liu LX, Kong CF, Zhou Q, Fei JM, Zhu YM, Liu H, Tang YC, Zhou CZ
- 399 Severe aconite poisoning successfully treated with veno-arterial extracorporeal membrane oxygenation: A case report
Kohara S, Kamijo Y, Kyan R, Okada I, Hasegawa E, Yamada S, Imai K, Kaizaki-Mitsumoto A, Numazawa S
- 405 Chemotherapy combined with bevacizumab for small cell lung cancer with brain metastases: A case report
Yang HY, Xia YQ, Hou YJ, Xue P, Zhu SJ, Lu DR
- 412 Diagnostic challenges and individualized treatment of cervical adenocarcinoma metastases to the breast: A case report
Akers A, Read S, Feldman J, Gooden C, English DP
- 418 Subsequent bilateral acute carpal tunnel syndrome due to tophaceous infiltration: A case report
Yeoh SC, Wu WT, Shih JT, Su WC, Yeh KT

- 425 Uniportal video-assisted thoracoscopic fissureless right upper lobe anterior segmentectomy for inflammatory myofibroblastic tumor: A case report
Ahn S, Moon Y
- 431 Hybrid treatment of varied orthodontic appliances for a patient with skeletal class II and temporomandibular joint disorders: A case report and review of literature
Lu T, Mei L, Li BC, Huang ZW, Li H
- 443 Significant improvement after sensory tricks and trunk strength training for Parkinson's disease with antecollis and camptocormia: A case report
Wang JR, Hu Y
- 451 Granulomatous mastitis in a 50-year-old male: A case report and review of literature
Cui LY, Sun CP, Li YY, Liu S
- 460 Double-chambered left ventricle with a thrombus in an asymptomatic patient: A case report
Kim N, Yang IH, Hwang HJ, Sohn IS

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Xin Ye, MD, Professor, Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, Shandong Province, China.
yexintaian2020@163.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Hua-Ge Yin*; Production Department Director: *Xu Guo*; Editorial Office Director: *Jin-Lei Wang*.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Salim Surani, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

January 16, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Primary biliary cholangitis presenting with granulomatous lung disease misdiagnosed as lung cancer: A case report

Shan-Li Feng, Jun-Yao Li, Chun-Ling Dong

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Gurakar A, United States

Received: September 19, 2023

Peer-review started: September 19, 2023

First decision: November 22, 2023

Revised: December 6, 2023

Accepted: December 25, 2023

Article in press: December 25, 2023

Published online: January 16, 2024



Shan-Li Feng, Jun-Yao Li, Chun-Ling Dong, Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun 130041, Jilin Province, China

Corresponding author: Chun-Ling Dong, PhD, Chief Physician, Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, No. 218 Ziqiang Street, Nangan District, Changchun 130041, Jilin Province, China. cldong@jlu.edu.cn

Abstract

BACKGROUND

There are few cases of pulmonary granulomatous changes secondary to primary biliary cirrhosis (PBC). No case of granulomatous lung disease secondary to PBC misdiagnosed as lung cancer had been reported.

CASE SUMMARY

A middle-aged woman presented with lung nodules and was misdiagnosed with lung cancer by positron emission tomography/computed tomography. She underwent left lobectomy, and the pathology of the nodules showed granulomatous inflammation, which was then treated with antibiotics. However, a new nodule appeared. Further investigation with lung biopsy and liver serology led to the diagnosis of PBC, and chest computed tomography indicated significant reduction in the pulmonary nodule by treatment with methylprednisolone and ursodeoxycholic acid.

CONCLUSION

Diagnosis of pulmonary nodules requires integrating various clinical data to avoid unnecessary pulmonary lobectomy.

Key Words: Granulomatous lung diseases; Primary biliary cirrhosis; Differential diagnosis; Misdiagnosis; Lung cancer; Case report

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Primary biliary cholangitis (PBC) can present as granulomatous lung disease when the lungs are involved. A patient with pulmonary granulomatous disease secondary to PBC was misdiagnosed with lung cancer by positron emission tomography/computed tomography (PET/CT), leading to unnecessary lobectomy. The symptoms and imaging of pulmonary granulomatous disease secondary to PBC are nonspecific. It also appears as high fluorodeoxyglucose uptake on PET/CT scan. Diagnosis should not rely solely on PET/CT findings but should consider clinical data, lung aspiration biopsy, and immune-related disease indexes to avoid unnecessary physical and financial burden.

Citation: Feng SL, Li JY, Dong CL. Primary biliary cholangitis presenting with granulomatous lung disease misdiagnosed as lung cancer: A case report. *World J Clin Cases* 2024; 12(2): 354-360

URL: <https://www.wjgnet.com/2307-8960/full/v12/i2/354.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v12.i2.354>

INTRODUCTION

Primary biliary cholangitis (PBC, formerly called primary biliary cirrhosis) is an immune-mediated and progressive intrahepatic cholestatic liver ailment of unknown etiology[1]. A variety of respiratory manifestations, including pulmonary granulomas, occur when the pulmonary system is affected[2]. Granulomatous lung diseases (GLDs) are heterogeneous, with multiple etiologies and nonspecific clinical and imaging manifestations. Differential diagnosis is challenging, and sometimes it is easy to misdiagnose granulomatous pulmonary disease as lung cancer. Therefore, positron emission tomography/computed tomography (PET/CT) offers more assistance in diagnosis. PET provides detailed information regarding the metabolism and function of a pulmonary nodule, whereas CT accurately identifies the location of the pulmonary nodule. Simultaneously, pathophysiological changes and the morphological structure of a pulmonary nodule are visualized by PET/CT, resulting in complementary functional and anatomical image information, which is of value in defining the nature of lung occupancy. However, there is an inaccuracy in identifying specific benign pulmonary nodules owing to the limitations of their functional diagnostic characteristics[3]. Comprehensive analysis of clinical data and well-timed tissue biopsies can reduce misdiagnoses.

In this case, we report a patient with pulmonary granulomas secondary to PBC misdiagnosed as lung cancer by PET/CT who was effectively treated with ursodeoxycholic acid (UDCA). We also reviewed the literature regarding pulmonary granulomas and pulmonary changes secondary to PBC. These documents help to explain the changes in pulmonary granuloma associated with PBC, which provides instructions and assistance to clinicians for diagnosis and treatment. Awareness of this identification can avoid disease progression and unnecessary physical injury.

CASE PRESENTATION

Chief complaints

A middle-aged woman presented to our outpatient clinic with a complaint of intermittent cough, a small amount of white foamy sputum with activity-related breathlessness for 5 mo, and the discovery of a new pulmonary nodule in the right lower lobe on chest CT 5 mo after pulmonary lobectomy.

History of present illness

Her symptoms started 5 mo before presentation, with intermittent cough and a small amount of white foamy sputum with activity-related breathlessness.

History of past illness

During a medical examination, two high-density pulmonary nodules were accidentally found by chest CT in the posterior basal segment of the left lower lobe in a middle-aged woman (Figure 1A). The pulmonary nodules displayed lobar and burr signs on chest CT and strong ¹⁸F-fluorodeoxyglucose (FDG) ingestion (SUV_{max} = 2.5, 4.5) on PET/CT, which led to misdiagnosis of lung cancer. Left lower lobectomy was offered to the patient in the hospital because of growing concern about the possibility of lung cancer, although the tumor marker levels were within the normal range. Both operative frozen section and postoperative pathological examination revealed pulmonary granuloma nodules and active epithelial cell proliferation. Morphologically, the diagnosis could not be determined, and a further clinical investigation was recommended to guide the diagnosis and treatment. However, the patient neglected the recommendation because of the absence of significant symptoms.

Personal and family history

The patient denied any family history of malignant tumors.

Physical examination

Physical examination was as follows: Body temperature, 36.5 °C; heart rate, 84 beats per min; respiratory rate, 16 breaths per min; and blood pressure, 126/81 mmHg. The skin and mucous membranes were free of yellow staining, rash, bleeding spots, liver palms, and spider nevus. The thorax was symmetrical, and the rib space was not widening or narrowed. Chest breathing was normal; respiratory movement was symmetrical; speech fibrillation was symmetrical bilaterally; both lungs were clear on percussion; voice conduction was normal; breath sounds in the left lower lung were diminished, and no obvious dry or wet rales were heard. There was no pleural friction sound.

Laboratory examinations

Laboratory tests indicated an elevated erythrocyte sedimentation rate (40 mm/h) and IgG (25.8 g/L) levels. Both alkaline phosphatase (322 U/L; normal, < 135 U/L) and -glutamyl transpeptidase (435 U/L; normal, < 45 U/L) exhibited marked elevation, while the tumor markers and tests of renal and thyroid function were normal. The outcome of T-SPOT [interferon (IFN)- γ release assay based on detecting IFN- γ secreted by T cells stimulated by specific *Mycobacterium tuberculosis* antigens] was negative. Screening of the antinuclear antibody (ANA) profiles revealed moderate positivity (++) for anti-52-kDa antibodies and weak positivity for Sjögren's syndrome A antigen (SS-A) antibodies, and indirect immunofluorescence (IIF) determined ANA titers to be 1:320. The serum tested for perinuclear anti-neutrophil cytoplasmic antibodies (ANCA) was positive. Microorganisms were not detected by metagenomic sequencing.

Imaging examinations

Chest CT revealed a pulmonary nodule in the right lower lobe (Figure 1B).

Further diagnostic work-up

The patient showed poor outcomes after anti-infective therapy with piperacillin sodium and sulbactam sodium. CT-guided percutaneous transthoracic needle biopsy of the pulmonary nodule was performed to clarify the diagnosis. The biopsy of a pulmonary nodule in the lower lobe of the right lung revealed granuloma formation (Figure 2A), fibrous hyperplasia in the pulmonary interstitium, and infiltration of lymphocytes, plasma cells and histiocytes (Figure 2B). Based on these clinical findings, tumors and infectious diseases were excluded. To exclude autoimmune liver disease, the patient was tested for autoantibodies against autoimmune liver diseases. The test revealed positivity (+++) for antibodies against GP210 and SP100 and weak positivity for autoantibodies to soluble liver antigens, while the antimitochondrial antibody (AMA) was negative. An invasive liver biopsy was advised for the patient for further definitive diagnosis. Unfortunately, the patient refused.

FINAL DIAGNOSIS

According to the American Association for the Study of Liver Diseases (AASLD), PBC was diagnosed considering the biochemical evidence of cholestasis and the presence of sp100 and gp210.

TREATMENT

The patient was started on UDCA and methylprednisolone.

OUTCOME AND FOLLOW-UP

Approximately 20 d later, the patient showed significant improvement in her symptoms and liver function tests. The patient's pulmonary nodule condition improved significantly, as evaluated by chest CT (Figure 3A). The patient continued to take UDCA and methylprednisolone for > 6 mo and was found to have a significant reduction in pulmonary nodular shadow by high-resolution thoracic CT (Figure 3B).

DISCUSSION

PBC is an immune-mediated, progressive intrahepatic cholestatic liver disease of unknown etiology that leads to cirrhosis, portal hypertension, and liver failure[4]. PBC is predominant in middle-aged women and presents as fatigue and itching, or is asymptomatic[5]. The pathogenesis of PBC needs to be clarified. Current data show that it is an autoimmune disease involving genetic susceptibility and environmental factors[6]. Antibodies are essential for diagnosing PBC, with AMAs being the hallmark. Furthermore, antibodies against gp210 and sp100 are commonly present in patients with AMA-negative PBC[7,8]. According to the AASLD, the diagnosis of PBC with negative AMA can be made without a liver biopsy when the following two criteria are fulfilled: (1) Presence of PBC-specific autoantibodies such as sp100 or gp210; and (2) Cholestasis with alkaline phosphatase and/or γ -glutamyltranspeptidase elevation[9].




Figure 1 Lung imaging before and after lobectomy. A: Chest computed tomography (CT) showed two high-density pulmonary nodules in the posterior basal segment of the left lower lobe; B: Chest CT revealed a new pulmonary nodule in the right lower lobe (left lateral position).





Figure 2 Hematoxylin-eosin staining of the biopsy specimen. A: Granuloma formation; B: Pulmonary interstitium infiltrated of lymphocytes, plasma cells, and histiocytes.

Extrahepatic autoimmune diseases can be found in 70%–85% of PBC patients. PBC is an autoimmune liver disease reported most frequently in pulmonary diseases. However, the incidence of PBC-related lung diseases is unknown[10]. Various pulmonary manifestations may occur in patients with PBC, including subclinical alveolitis, GLD, airway disease, pulmonary hypertension, pulmonary hemorrhage, and pleural effusion[11]. Few studies have reported the histopathological features of the lungs. Frechen *et al*[12] reported a case of pulmonary necrotizing granulomatosis in a patient with PBC. Lee *et al*[13] analyzed 16 patients with PBC who underwent lung biopsy and found that 13 had pathological manifestations of non-necrotizing granulomas and lymphocyte infiltration, which parallel histopathology in our case. This indicates that pulmonary disease secondary to PBC should be considered regarding the differential diagnosis of GLD.

In our case, the patient was found to have a pulmonary nodule on incidental physical examination. The initial chest CT findings revealed a lung nodule showing lobulated, burred, and irregular margins, features reminiscent of a lung malignancy. Furthermore, the nodule was found to show high FDG uptake on PET/CT. ^{18}F -FDG-PET/CT is now widely used in the differential diagnosis of benign and malignant diseases. FDG-PET can measure the uptake of the glucose analog FDG to assess glucose metabolism. Tumor FDG uptake is based on tumor hyperglycolysis, but FDG is not a specific tracer, as high FDG uptake also occurs in inflammatory or infectious pathologies[14]. Therefore, clinicians should not hastily rely on PET/CT results for pulmonary nodules of unknown etiology.

GLDs represent a group of heterogeneous diseases with a myriad of etiologies, classified into infectious (fungus and tuberculosis) and noninfectious lung diseases (allergic pneumonia, sarcoidosis, granulomatosis with polyangiitis (GPA),



DOI: 10.12998/wjcc.v12.i2.354 Copyright ©The Author(s) 2024.

Figure 3 Pulmonary imaging findings on post-treatment review. A: After approximately 20 d of ursodeoxycholic acid (UDCA) and methylprednisolone treatment, the nodular shadow was improved in chest computed tomography (CT) images; B: High-resolution thoracic CT images revealed significant improvement in the nodular shadow after > 6 mo of UDCA and methylprednisolone treatment.

and eosinophilic granulomatosis with polyangiitis (EGPA)[15]. The lack of specificity in clinical manifestations and chest CT findings makes definitive diagnosis difficult. The high rate of false positives makes it difficult to distinguish between GLDs and malignancy using FDG-PET/CT. Pulmonary granulomatous disease secondary to PBC is frequently observed in middle-aged women and is characterized by symptoms such as dyspnea, dry cough, and systemic symptoms. Chest X-rays or CT scans can show pulmonary nodules, interstitial changes, or lung infiltrates, which may resemble those of lung cancer or other GLDs, potentially resulting in misdiagnosis. The patient in this case was discovered to have a pulmonary nodule with initial chest CT findings showing lobulated, burred, and irregular margins and high FDG uptake on PET/CT, mistakenly suggestive of lung malignancy. Therefore, specific symptoms and typical extrapulmonary manifestations are indicative. For example, GLD combined with keratitis, conjunctivitis, scleritis, oral ulcer gingivitis, and proteinuria often indicate GPA, while EGPA is often associated with multiple mononeuropathy[16-18]. In our case, the presence of positive antibodies for autoimmune liver disease, along with significantly elevated levels of alkaline phosphatase and -glutamyl transpeptidase, substantially supports the diagnosis of PBC.

A pulmonary biopsy is needed for atypical clinical presentations or to exclude pulmonary malignancy. The characteristics of lung granulomas differ depending on the cause, making pathological features crucial for diagnosis. It mainly includes granuloma distribution, necrosis, pathogens, and other concomitant features[19]. Angiocentric distribution is usually linked with granulomatous vasculitis, and lymphatic distribution is mainly found in nodular disease. The presence of granulomatous necrosis should always alert clinicians to the possibility of infection. However, necrosis may also occur in noninfected granulomas. In terms of other concomitant features, different GLDs are accompanied by differences in inflammatory cell infiltration. For example, the granulomatous inflammatory response in sarcoidosis is usually less mild with only a small number of lymphocytes, while allergic pneumonia is often infiltrated with abundant lymphocytes and plasma cells. In addition, vasculitis is mainly found in granulomatous vasculitis inflammation, including Wegener's granulomatosis, allergic vasculitis granulomatosis, and lymphomatoid granulomatosis[20]. Infection must first be carefully excluded in patients with GLD by special staining to identify the appropriate pathogens. In patients with pathological tissue showing noninfectious granulomas, clinicians should actively determine the pathological tissue features, such as granuloma distribution, presence or absence of necrosis, and vasculitis, to make the correct diagnosis[21]. Pulmonary nodule distribution, size, morphology, type of inflammatory cells, presence of vasculitis, and necrosis contribute to distinguishing granulomas of different etiologies. Pathological examination sometimes does not yield a definitive diagnosis, as misdiagnoses are commonly made due to large interobserver variability among pathologists, the impact of different disease processes, and overlapping histopathology in some diseases[22]. Therefore, defining the pathogenesis of GLD depends on multidisciplinary assessment because pulmonary granuloma is a nonspecific histopathological discovery.

CONCLUSION

In summary, GLDs are insidious diseases with multiple etiologies and nonspecific manifestations in clinical symptoms and imaging findings. PBC should be considered in the differential diagnosis of GLD. Reliance solely on PET/CT for indeterminate pulmonary nodules is discouraged, and a comprehensive evaluation including clinical, pathological and immunological markers is essential. Identifying and categorizing autoimmune conditions is crucial for the diagnosis and treatment of GLD. Heightened awareness and caution regarding autoimmune-related GLDs can prevent unwarranted surgical procedures and decrease instances of misdiagnosis.

FOOTNOTES

Author contributions: Feng SL wrote the original draft; Feng SL and Dong CL collected and analyzed the clinical data; Dong CL and Li JY reviewed and edited the manuscript; Dong CL contributed to conceptualization and supervision; All authors have read and approved the final manuscript.

Supported by The Special Health Project of the Department of Finance of Jilin Province, China, No. 2020SCZT023 and No. 3D5177713429.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Shan-Li Feng 0000-0002-9365-5043; Jun-Yao Li 0000-0003-2866-3298; Chun-Ling Dong 0000-0002-6389-5011.

S-Editor: Fan JR

L-Editor: Kerr C

P-Editor: Xu ZH

REFERENCES

- 1 Lleo A, Leung PSC, Hirschfield GM, Gershwin EM. The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. *Semin Liver Dis* 2020; **40**: 34-48 [PMID: 31537031 DOI: 10.1055/s-0039-1697617]
- 2 Floreani A, Cazzagon N. PBC and related extrahepatic diseases. *Best Pract Res Clin Gastroenterol* 2018; **34-35**: 49-54 [PMID: 30343710 DOI: 10.1016/j.bpg.2018.05.013]
- 3 Anan N, Zainon R, Tamal M. Correction: A review on advances in 18F-FDG PET/CT radiomics standardisation and application in lung disease management. *Insights Imaging* 2022; **13**: 32 [PMID: 35226198 DOI: 10.1186/s13244-022-01186-8]
- 4 Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. *Lancet* 2020; **396**: 1915-1926 [PMID: 33308474 DOI: 10.1016/S0140-6736(20)31607-X]
- 5 Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HLA, Hansen BE; Global PBC Study Group. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. *Clin Gastroenterol Hepatol* 2019; **17**: 2076-2084.e2 [PMID: 30616022 DOI: 10.1016/j.cgh.2018.12.028]
- 6 Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM; USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. *Hepatology* 2005; **42**: 1194-1202 [PMID: 16250040 DOI: 10.1002/hep.20907]
- 7 Hu SL, Zhao FR, Hu Q, Chen WX. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. *PLoS One* 2014; **9**: e101916 [PMID: 25010534 DOI: 10.1371/journal.pone.0101916]
- 8 Levy C, Bowlus CL. Role of Antinuclear Antibodies in Primary Biliary Cholangitis. *Am J Gastroenterol* 2020; **115**: 1604-1606 [PMID: 32701734 DOI: 10.14309/ajg.0000000000000765]
- 9 Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2019; **69**: 394-419 [PMID: 30070375 DOI: 10.1002/hep.30145]
- 10 Wallace JG Jr, Tong MJ, Ueki BH, Quismorio FP. Pulmonary involvement in primary biliary cirrhosis. *J Clin Gastroenterol* 1987; **9**: 431-435 [PMID: 3655277 DOI: 10.1097/00004836-198708000-00015]
- 11 Akulkina LA, Brovko MY, Sholomova VI, Rozina TP, Yanakayeva AS, Frantsuzovich LY, Lebedeva MV, Fomin VV. Variety of lung involvement in autoimmune liver diseases. *Ter Arkh* 2018; **90**: 107-112 [PMID: 30701952 DOI: 10.26442/terarkh2018908107-112]
- 12 Frechen D, Cornelissen C, Schreiner K, Jäkel J, Krüger S. [Pulmonary necrotizing sarcoid granulomatosis in a patient with primary biliary cirrhosis]. *Dtsch Med Wochenschr* 2010; **135**: 1733-1736 [PMID: 20812157 DOI: 10.1055/s-0030-1263308]
- 13 Lee HE, Churg A, Ryu JH, Bilawich AM, Larsen BT, Tazelaar HD, Yi ES. Histopathologic findings in lung biopsies from patients with primary biliary cholangitis. *Hum Pathol* 2018; **82**: 177-186 [PMID: 30067952 DOI: 10.1016/j.humpath.2018.07.021]
- 14 Groheux D, Quere G, Blanc E, Lemarignier C, Vercellino L, de Margerie-Mellon C, Merlet P, Querellou S. FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review. *Diagn Interv Imaging* 2016; **97**: 1003-1017 [PMID: 27567555 DOI: 10.1016/j.diii.2016.06.020]
- 15 Stellmacher F, Perner S. [Overview: granulomatous diseases of the lung]. *Pathologe* 2021; **42**: 64-70 [PMID: 33475808 DOI: 10.1007/s00292-020-00893-7]

- 16 **Chopra A**, Avadhani V, Tiwari A, Riemer EC, Sica G, Judson MA. Granulomatous lung disease: clinical aspects. *Expert Rev Respir Med* 2020; **14**: 1045-1063 [PMID: [32662705](#) DOI: [10.1080/17476348.2020.1794827](#)]
- 17 **Casal A**, Díaz-Garel J, Pereiro T, Toubes ME, Ricoy J, Valdés L. Pulmonary vasculitis. *J Thorac Dis* 2018; **10**: 5560-5575 [PMID: [30416807](#) DOI: [10.21037/jtd.2018.08.117](#)]
- 18 **Batra K**, Chamrathy M, Chate RC, Jordan K, Kay FU. Pulmonary vasculitis: diagnosis and endovascular therapy. *Cardiovasc Diagn Ther* 2018; **8**: 297-315 [PMID: [30057877](#) DOI: [10.21037/cdt.2017.12.06](#)]
- 19 **El-Zammar OA**, Katzenstein AL. Pathological diagnosis of granulomatous lung disease: a review. *Histopathology* 2007; **50**: 289-310 [PMID: [17257125](#) DOI: [10.1111/j.1365-2559.2006.02546.x](#)]
- 20 **Respiratory Pathology Committee of Chinese Association of Chest Physician and Expert Group on Consensus Preparation.** [Recommendation on the principle and procedure of pathological diagnosis of pulmonary granulomatous diseases]. *Zhonghua Bing Li Xue Za Zhi* 2021; **50**: 719-727 [PMID: [34405604](#) DOI: [10.3760/cma.j.cn112151-20210128-00092](#)]
- 21 **Samsonova MV**, Chernyaev AL. [Histological differential diagnosis of granulomatous lung diseases (part I)]. *Arkh Patol* 2019; **81**: 65-70 [PMID: [30830108](#) DOI: [10.17116/patol20198101165](#)]
- 22 **Ohshimo S**, Guzman J, Costabel U, Bonella F. Differential diagnosis of granulomatous lung disease: clues and pitfalls: Number 4 in the Series "Pathology for the clinician" Edited by Peter Dorfmueller and Alberto Cavazza. *Eur Respir Rev* 2017; **26** [PMID: [28794143](#) DOI: [10.1183/16000617.0012-2017](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

